MIRA's SKNY-1 shows favorable oral bioavailability, brain penetration in preclinical studies

MIRA PHARMACEUTICALS, INC.

Optimized oral formulation of SKNY-1 demonstrated favorable oral bioavailability and reproducible systemic exposure in preclinical PK study.
Robust brain penetration and substantial liver exposure observed; peak plasma concentrations at 6-12 hours support once-daily oral dosing.
Findings complement prior efficacy studies showing weight reduction, lean mass preservation, and reduced compulsive feeding/nicotine-seeking.
SKNY-1 designed with biased CB1 modulation, CB2 agonism, and selective MAO-B inhibition; no anxiety-like behavior in preclinical model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.